drugset

drugset / Trial / NCT04176757

A Study of ZN-c5 in Participants With Breast Cancer

NCT04176757 ↗

Phase 1 Completed 35 enrolled Zeno Alpha Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1 open-label, multicenter study to evaluate biomarkers for ZN-c5 in subjects with breast cancer

Timeline

Start: 2020-01-03
Primary completion: 2021-04-27
Completion: 2021-05-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ZN-c5	Unknown	—	Oral

Indications